Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2017-04-07
Source Title
World Journal of Gastroenterology
Journal Title
Journal ISSN
Volume Title
Publisher
Baishideng Publishing Group Inc.
Melbourne Authors
Affiliation
Biochemistry and Molecular Biology
Document Type
Journal Article
Subject Code
Citation
Diwakarla, C., Hannan, K., Hein, N. & Yip, D. (2017). Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. World Journal of Gastroenterology, 23 (13), pp.2276-2285. https://doi.org/10.3748/wjg.v23.i13.2276.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Pancreatic ductal adenocarcinoma is a devastating disease with a poor prognosis regardless of stage. To date the mainstay of therapy for advanced disease has been chemotherapy with little incremental improvements in outcome. Despite extensive research investigating new treatment options the current practices continue to utilise fluorouracil or gemcitabine containing combinations. The need for novel therapeutic approaches is mandated by the ongoing poor survival rates associated with this disease. One such approach may include manipulation of ribosome biogenesis and the nucleolar stress response, which has recently been applied to haematological malignancies such as lymphoma and prostate cancer with promising results. This review will focus on the current therapeutic options for pancreatic ductal adenocarcinoma and the complexities associated with developing novel treatments, with a particular emphasis on the role of the nucleolus as a treatment strategy.